Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 7c, updates guidance
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.80 -2.68%
EPS Growth %: -30.4%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -30.4%
Financial Fact:
Cost of sales, product: 6.99M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of ($0.09), $0.07 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $47.7 million versus the consensus estimate of $50.75 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2024 revenue of $190-210 million, versus the consensus of $197.4 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kalshi in early talks for IPO - The Information
- Huntington Ingalls wins $418M Navy contract
- Pfizer reaffirms 2026 guidance after CFO transition news
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
